by H.S. Ayoub
BioHealth Investor.com
Biotechnology
LPATH INC [LPTN.OB] +14.41%
HANA BIOSCIENCES INC [HNAB] +12.94%
NASTECH PHARM CO [NSTK] +10.86%
PIPEX PHARMACEUTICAL [PPXP.OB] +9.96%
ALFACELL CORP [ACEL] +8.98%
Diagnostic Substances
EPICEPT CORPORATION [EPCT] +73.25%
MONOGRAM BIOSCIENCES [MGRM] +11.06%
AVANT IMMUNOTHERAP [AVAN] +6.90%
PALATIN TECH INC [PTN] +4.66%
GENE LOGIC INC [GLGC] +4.57%
Drug Delivery
DELCATH SYSTEMS INC [DCTH] +6.84%
ALKERMES INC [ALKS] +2.91%
INSITE VISION INC [ISV] +2.60%
NEKTAR THERAPEUTIC [NKTR] +2.55%
NOVEN PHARMACEUTIC [NOVN] +2.35%
Drug Manufacturers
AVANIR PHARMACEUTICL [AVNR] +12.82%
POZEN INC [POZN] +7.32%
PROVECTUS PHARMA [PVCT.OB] +5.10%
OSCIENT PHARMACEUT [OSCI] +4.27%
JAVELIN PHARMACEUTIC [JAV] +3.52%
Drug Related Products
PRESTIGE BRAND HLGS [PBH] +4.41%
MANNATECH INC [MTEX] +1.85%
PACIFICHEALTH LABS [PHLI.OB] +1.74%
PERRIGO COMPANY [PRGO] +1.53%
LABOPHARM INC. [DDSS] +1.43%
Generic Drugs
CATALYST PHARMACEUTI [CPRX] +6.80%
ISOLAGEN INC [ILE] +1.74%
CARACO PHARMA LABS [CPD] +1.69%
WATSON PHARMACEUTCLS [WPI] +1.24%
HI-TECH PHARMACAL [HITK] +0.87%
Medical Appliances & Equipment
Supplies
NON INVASIVE MONITORNG SYS NEW [NIMU.OB] +9.93%
INTUITIVE SURG INC [ISRG] +8.71%
ALIGN TECHNOLOGY I [ALGN] +5.02%
NATUS MEDICAL INC [BABY] +4.50%
STEREOTAXIS, INC. [STXS] +4.11%
Medical Instruments & Supplies
VYTERIS HOLDINGS NV [VYHN.OB] +26.05%
ATRICURE, INC. [ATRC] +7.35%
BIOFORCE NANOSCIENCE [BFNH.OB] +4.90%
CRYOCOR, INC. [CRYO] +4.79%
KENSEY NASH CP [KNSY] +4.57%
Medical Laboratories & Research
SPHERIX INC [SPEX] +4.51%
MEDTOX SCIENTFIC INC [MTOX] +3.07%
OSI PHARMACEUTIC [OSIP] +2.18%
BIO-REFERENCE LAB [BRLI] +2.14%
ENZO BIOCHEM INC [ENZ] +1.24%
http://www.biohealthinvestor.com/
Buffett Missed These Two…
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.